EC-401

EC-401 is an experimental, extended-release intravitreal therapeutic being developed by Eclipse Life Sciences for the treatment of retinal diseases. It is designed to provide both anti-inflammatory and anti-fibrotic activity, specifically targeting wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) that is resistant to standard anti-VEGF monotherapy. The designation 'CaM-I' suggests that the drug functions as a calmodulin inhibitor, a mechanism intended to address the underlying inflammatory and fibrotic processes in the retina. By utilizing an extended-release formulation for intravitreal administration, EC-401 aims to provide sustained therapeutic levels of the drug while reducing the frequency of ocular injections required for patients.